‘This R&D Malarkey, it’s broken, isn’t it?’
March 9, 2011Research and Development R&D, Sandwich, research productivity
Pharmaceutical industry leaders are increasingly admitting that the very low productivity of its R&D pipelines is unsustainable – but no …
Francois Meyer to head up TxCell
March 9, 2011Research and Development Francois Meyer, TxCell, appointment, research and development
French biotech TxCell has appointed François Meyer as chief executive. He has more than 25 years of pharma and biotech …
Janssen’s monthly antipsychotic approved in Europe
March 9, 2011Sales and Marketing Janssen, Xeplion, antipsychotic, injectible antipsychotic, paliperidone palmitate, schizophrenia
Janssen’s injectable antipsychotic Xeplion has been approved by the European Commission for the treatment of schizophrenia. There is no cure …
Actelion defends itself against investor aggression
March 9, 2011Sales and Marketing Actelion, Tracleer, almorexant
Swiss biotech firm Actelion is mounting a defence of its management board and strategy following an offensive by a shareholder …
Finance a bigger worry than reform for NHS chiefs
March 9, 2011Acute Trusts, NHS, NHS Confederation, NHS finances, NHS reforms
NHS leaders are more concerned with how they are going to balance the books this year than with the reorganisation …
AZ partners with Galderma on psoriasis research
March 9, 2011Research and Development AZ, AstraZeneca, Galderma, dermatology, psoriasis
AstraZeneca has signed a five-year deal with dermatology specialist Galderma Pharma to develop new treatments for conditions including psoriasis. It …
Health secretary defends NHS reform to doctors
March 8, 2011GP consortia, Health and Social Reform bill, NHS, NHS reforms
Health secretary Andrew Lansley has defended his reorganisation of the NHS to doctors, saying it will cut unnecessary levels of …
Eisai confirms 20% cut in US workforce
March 8, 2011Manufacturing and Production, Research and Development, Sales and Marketing Aricept, Eisai, Halaven, US, donepezil, eribulin, pharma job cuts
Eisai’s planned job cuts will fall heaviest on its US operations, where 20% of the workforce will be let go …
Sophie Gibbs and Naumaan Mayet join Pan
March 8, 2011Medical Communications, Sales and Marketing Naumaan Mayet, Pan, Pan Advertising, Sophie Gibbs, appointment, medical communications
Pan Advertising has recruited two new members to its account handling team.Sophie Gibbs returns to the agency as an account …
Merck says sale of Oss facility would be too expensive
March 8, 2011Manufacturing and Production, Research and Development Holland, Merck & Co, Oss, Oss pharma research, Pantarhei Bioscience
The debate around the closure of Merck & Co’s R&D and manufacturing unit in Oss, the Netherlands, rumbles on, with …
AZ stops making Pulmicort pMDI inhaler
March 8, 2011Manufacturing and Production AZ, AstraZeneca, Pulmicort, Pulmicort pMDI, Skyepharma, asthma, asthma inhaler, budesonide
AstraZeneca has discontinued production of its Pulmicort pMDI asthma inhaler because of manufacturing issues, and looks set to exit from …
Helsinn expands high-potency plant with cytotoxics suite
March 8, 2011Manufacturing and Production APIs, CMOs, GMP, Helsinn, Helsinn Advanced Synthesis, Swiss pharma contract manufacturing, contract manufacturing, high-potency APIs
Helsinn is on track to complete construction of a new manufacturing plant for cytotoxic active pharmaceutical ingredients in Biasca, Switzerland, …
Pharma manufacturing news in brief
March 8, 2011Manufacturing and Production Bristol-Myers Squibb, CSM GlobalPharma, Carbogen Amcis, Quotient Clinical, SCM Pharma, WuXi PharmaTech
Facility updates from Bristol-Myers Squibb, WuXi PharmaTech, Quotient Clinical, CSM GlobalPharma and SCM Pharma, plus a reorganisation of Carbogen Amcis’ …
Ethical practices – pharma’s obligation
March 8, 2011Research and Development, Sales and Marketing ethics, industry relations, industry reputation
Pharmaceutical companies are not charities, and neither is any other business, by definition. Capitalism as a recognised system has been …
Service Insight: Emerging markets – a business development task or extreme fishing?
March 7, 2011Sales and Marketing Service Insight, Surelines Ltd, emerging markets
SERVICE INSIGHTEmerging markets, new business; call it what you will but invariably the responsibility for grasping this nettle falls to …
GSK ends neuroscience research alliance
March 7, 2011Research and Development GSK, GlaxoSmithKline, Targacept, neuronal nicotinic receptors, neuroscience research
GlaxoSmithKline has severed a strategic alliance formed in July 2007 with US biopharma company Targacept. GSK forked out $45 million …
GSK adds former Merck CFO to board
March 7, 2011Sales and Marketing GSK, GlaxoSmithKline, Judy Lewent, Stacey Cartwright, appointment, sales and marketing
GlaxoSmithKline has appointed Judy Lewent to its board as a non-executive director. She has previously served as an executive VP …
Government injects £775m into NHS translational research
March 7, 2011Research and Development ABPI, Kent, NHS research, Pfizer research Kent, Sandwich, Science and Technology Select Committee, translational research
The government has pledged around £775 million for translational research, saying it will help modernise the health service and support …
Eisai prepares ground for Halaven’s European launch
March 7, 2011Sales and Marketing Cancer, EMBRACE, Eisai, Halaven, advanced breast cancer, breast cancer, eribulin
Eisai has published further details of a phase III trial of its first-in-class chemotherapy drug Halaven ahead of its hoped-for …
Eisai to cut 900 jobs ahead of Aricept patent loss
March 7, 2011Sales and Marketing Aricept, Eisai, donepezil, generics, job cuts
Eisai is to cut around 900 jobs in Europe, the US and Japan over the next five years as it …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
